Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2010https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2010
Retrieved on: 
목요일, 4월 18, 2024
Information
Tags: 
Eurostat, Diagnosis, Civil service commission, SMN, Brain, Atrophy, Gene, Weakness, Spinal muscular atrophy, Survival, Medicine, Disease, Paralysis, Novartis, Patient, Committee, Knowledge, Ventilation, Regulation, Brain cell, EMA, IRIS, Mouth, European, COMP, Spinal cord, Sponsor, European Commission, Spine, Safety, SMN1, Marketing, SMN2, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, ICELAND, EU, NORWAY, UNITED KINGDOM, LIECHTENSTEIN, IRELAND
요약
Key Points: 


Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Copyright: 
2024 European Medicines Agency. All Rights Reserved.